fbpx

CEO Confidential

World’s 20 most attractive biopharmaceutical employers for 2016, according to Science magazine

Pharmaceutical industry

In a new analysis by the Science magazine, Regeneron Pharmaceuticals was found to be world’s most attractive biopharmaceutical company worldwide. The top three companies in the list – Regeneron Pharmaceuticals, Novo Nordisk, and Moderna Therapeutics.

Eli Lilly and Company ranked No. 4 among biotechnology and pharmaceutical companies worldwide. The survey features the 20 best companies in the biotechnology, biopharmaceutical, pharmaceutical and related industries.

The survey, which lists the top 20 employers, noting its performance in areas such as financial strength, easy adaptation to change and a research-driven environment.

So which biotechnology and pharmaceutical companies made Science magazine’s global top 20?

1. Regeneron Pharmaceuticals (Tarrytown, NY)

2. Novo Nordisk (Bagsvaerd, Denmark)

3. Moderna Therapeutics (Cambridge, MA)

4. Eli Lilly and Company (Indianapolis, IN)

5. Vertex Pharmaceuticals (Boston, MA)

6. Novozymes (Bagsvaerd, Denmark)

7. Genentech (South San Francisco, CA)

8. Alexion Pharmaceuticals (New Haven, CT)

9. Biocon (Bangalore, India)

10. Roche—excluding Genentech (Basel, Switzerland)

11. Merck KGaA (Darmstadt, Germany)

12. AbbVie (North Chicago, IL)

13. Monsanto Company (Creve Coeur, MO)

14. Syngenta (Basel, Switzerland)

15. Abbott (Abbott Park, IL)

16. Boehringer Ingelheim (Ingelheim, Germany)

17. Celgene Corporation (Summit, NJ)

18. Bayer (Leverkusen, Germany)

19. Novartis (Basel, Switzerland)

20. Johnson & Johnson (New Brunswick, NJ)

Leave a Reply



Follow us on Facebook, Twitter, Instagram, and Linkedin to never miss an update from the CEOWORLD magazine.
Dr. Amarendra Bhushan Dhiraj
Dr. Amarendra Bhushan Dhiraj is the CEO and editorial director at CEOWORLD magazine, the leading global business magazine written strictly for CEOs, CFOs, top managers, company directors, investors, senior executives, business leaders, and high net worth individuals.
Share via